Trident Lifeline Peer Comparison
BSE: 543616
₹267.35
As on 28-Aug-2026IST
Market cap
₹319 Cr
Revenue (TTM)
₹87 Cr
P/E Ratio
16.8
P/B Ratio
3.3
Div. Yield
0 %
| Trident Lifeline | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
319 | 38,731 | 21,501 | 19,125 | 18,253 |
Revenue (₹ Cr) |
87 | 4,148 | 2,570 | 2,287 | 3,230 |
Net Profit (₹ Cr) |
10.49 | 709.47 | 735.15 | 678.07 | 666.92 |
Net Margin (%) |
11.02 | 16.85 | 26.88 | 28.10 | 20.60 |
RoE (%) |
18.78 | 19.11 | 19.16 | 19.73 | 18.75 |
Price to Earnings |
16.75 | 54.59 | 29.25 | 28.74 | 28.35 |
Price-To-Book |
3.26 | 9.31 | 4.88 | 5.08 | 4.51 |
Income Statement (₹ Cr)
| Trident Lifeline | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Operating Revenue
|
86.96 | 3,917.99 | 2,281.35 | 1,937.47 | 2,893.64 |
|
Total Income
|
95.20 | 3,957.03 | 2,453.60 | 2,033.90 | 2,912.00 |
|
Total Expenditure
|
71.95 | 2,886.87 | 1,541.03 | 1,290.54 | 1,876.44 |
|
EBITDA
|
15.02 | 1,031.12 | 740.32 | 646.93 | 1,017.20 |
|
Depreciation
|
5.49 | 171.04 | 60.79 | 65.96 | 315.46 |
|
EBIT
|
9.52 | 860.08 | 679.53 | 580.97 | 701.74 |
|
Interest
|
4.14 | 11.73 | 8.50 | 0.61 | 231.29 |
|
Other Income
|
8.23 | 39.04 | 172.25 | 96.43 | 18.36 |
|
Exceptional Items
|
-- | -- | 172.81 | -- | -- |
|
Profit before Tax
|
13.61 | 887.39 | 1,016.09 | 676.78 | 488.87 |
|
Provision for Tax
|
3.12 | 227.81 | 248.49 | 135.69 | 114.20 |
|
Profit after Tax
|
10.49 | 659.58 | 767.60 | 541.09 | 374.67 |
Liabilities (₹ Cr)
| Trident Lifeline | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
64.46 | 3,433.32 | 4,217.41 | 2,850.49 | 2,854.36 |
|
Minority Interest
|
5.19 | -- | -- | 35.90 | 417.40 |
|
Non-Current Liabilities
|
30.40 | 443.23 | 54.89 | 13.24 | 2,100.97 |
|
Current Liabilities
|
55.20 | 1,156.93 | 569.51 | 305.99 | 1,489.55 |
|
Total Liabilities
|
157.20 | 5,033.48 | 4,911.11 | 3,207.85 | 6,862.28 |
Assets (₹ Cr)
| Trident Lifeline | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
60.60 | 2,586.15 | 1,328.96 | 1,071.67 | 5,531.13 |
|
Current Assets
|
92.02 | 2,447.33 | 3,512.85 | 2,133.95 | 1,331.15 |
|
Total Assets
|
157.20 | 5,033.48 | 4,911.11 | 3,207.85 | 6,862.28 |
|
Total Debt*
|
54.03 | 13.80 | 2.50 | 0.55 | 2,421.66 |
|
Net Current Assets
|
36.82 | 1,290.40 | 2,943.34 | 1,827.96 | -158.40 |
|
Contingent Liabilities
|
17.00 | 131.94 | 363.79 | 0.64 | 64.29 |
Cashflow (₹ Cr)
| Trident Lifeline | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-10.24 | 902.45 | 659.75 | 432.37 | 1,065.01 |
|
Cash Flow from Investing Activities
|
-13.82 | -295.90 | -71.34 | -334.73 | -79.97 |
|
Cash from Financing Activities
|
19.76 | -579.67 | -205.34 | -38.32 | -881.32 |
|
Net Cash Inflow / Outflow
|
-4.31 | 26.88 | 383.07 | 59.32 | 103.72 |
Ratios
Profitability Ratios
| Trident Lifeline | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
ROCE (%)
|
19.17 | 26.73 | 26.21 | 26.22 | 13.59 |
|
ROE (%)
|
18.78 | 21.81 | 19.65 | 21.72 | 13.81 |
|
ROA (%)
|
8.64 | 13.58 | 17.03 | 18.37 | 5.48 |
|
EBIT Margin (%)
|
26.73 | 27.31 | 40.00 | 38.37 | 35.79 |
|
Net Margin (%)
|
11.02 | 16.67 | 31.28 | 26.60 | 12.87 |
|
Cash Profit Margin (%)
|
18.38 | 20.46 | 34.70 | 31.33 | 23.22 |
Growth Ratios
| Trident Lifeline | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
94.86 | 12.45 | 4.02 | 14.37 | 44.02 |
|
EBIT Growth (%)
|
125.42 | 14.56 | 11.86 | 20.21 | 48.22 |
|
Net Profit Growth (%)
|
76.69 | 19.35 | 39.23 | 17.27 | -5.65 |
|
EPS Growth (%)
|
85.19 | 18.98 | 39.23 | 17.25 | -10.39 |
|
Book Value Growth (%)
|
23.80 | 17.31 | 17.30 | 23.77 | 10.19 |
Valuation Ratios
| Trident Lifeline | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Price / Earnings
|
25.16 | 38.29 | 23.86 | 28.38 | 54.83 |
|
Price / Book Value
|
4.78 | 7.73 | 4.34 | 5.52 | 6.78 |
|
Dividend Yield (%)
|
0.00 | 0.96 | 4.12 | 0.30 | 0.52 |
|
EV/EBITDA
|
14.93 | 23.49 | 17.01 | 19.78 | 20.75 |
|
Market Cap (₹ Cr)
|
295.53 | 25,253.79 | 18,318.10 | 15,219.80 | 19,292.77 |
Solvency Ratios
| Trident Lifeline | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.87 | 0.00 | 0.00 | 0.00 | 0.85 |
|
Short term debt to equity ratio
|
0.26 | 0.00 | 0.00 | 0.00 | 0.14 |
|
Current Ratio
|
1.67 | 2.12 | 6.17 | 6.97 | 0.89 |
|
Quick Ratio
|
1.16 | 1.66 | 5.33 | 5.88 | 0.67 |
|
Interest Coverage
|
4.29 | 76.66 | 120.54 | 1,110.48 | 3.11 |
Operating Efficiency Ratios
| Trident Lifeline | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
31.83 | 20.81 | 8.46 | 32.65 | 15.85 |
|
Asset Turnover
|
0.72 | 0.84 | 0.53 | 0.66 | 0.43 |
|
Receivable days
|
86.30 | 67.54 | 29.10 | 110.70 | 54.07 |
|
Inventory Days
|
85.68 | 46.37 | 69.53 | 65.86 | 32.16 |
|
Payable days
|
110.89 | 106.33 | 76.77 | 105.88 | 140.91 |
|
Cash Conversion Cycle
|
61.09 | 7.58 | 21.86 | 70.68 | -54.68 |